Lexaria Bioscience Corp. LEXX 深 沪
等待开盘 07-14 09:30:00 美东时间
0.5949
-0.052
-8.00%
华盛通- 最 高0.6786
- 今 开0.6786
- 成交量 6.27万股
- 最 低 0.5688
- 昨 收 0.6466
- 总市值 1474.61万
- 52周最高 1.55
- 市盈率 静 --
- 换手率 0.25%
- 52周最低 0.46
- 委 比 99.02%
- 总股本 2478.74万
- 历史最高 12.50
- 量 比 0.79
- 振 幅 16.98%
- 历史最低 0.46
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexaria Bioscience Q3 EPS $(0.08) Beats $(0.09) Estimate
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 0 percent. This is a 61.9 percent increase over losses of $(0.21) per share from the same period last year.
今天 06:00
Lexaria Bioscience Announces It Began Dosing On June 14 In Its Human Study GLP-1-H26-7 Evaluating Two Oral DehydraTECH-Semaglutide Compositions Against Wegovy
Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing began on schedule on June 14th with Human Pilot Study #7 (GLP-1-H26-7) that is evaluating two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo ...
06-25 21:14
Lexaria Bioscience Receives Ethics Approval For Human GLP-1 Study Comparing Oral DehydraTECH-Semaglutide Formulations To Wegovy, With Dosing Expected To Begin In Mid-June
Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an independent review board, for
05-19 21:17
Lexaria Bioscience Advances Human Study Of DehydraTECH-Semaglutide Versus Wegovy Tablets
Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral
05-05 21:22
Lexaria Bioscience Engages The Contract Research Organization To Execute And Report On Its 2026 Animal Study #2 That Will Evaluate A Number Of Formulation Enhancements With Two Next-Generation GLP-1 Drugs In Animals
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and
04-23 21:09
Lexaria Engages CRO To Execute, Report On 2026 Animal Study GLP-1-A26-1 Evaluating Formulation Enhancements Using Both DHT-Sema GLP-1 And DHT-CBD Compositions To Explore Potential For Additional Improved Performance And Stake New IP Claims
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and
04-15 21:19
Lexaria Bioscience Q2 EPS $(0.06) Beats $(0.11) Estimate, Sales $20.000K Miss $100.000K Estimate
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 60 percent increase over losses of $(0.15) per share from
04-14 05:20
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Profusa (NASDAQ:PFSA) stock rose 48.6% to $0.86 during Thursday's regu...
04-03 01:05
Lexaria Bioscience Receives 5 New Patents Including 2 For Diabetes Treatment Utilizing GLP-1 Drugs
Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this update on additional new intellectual property ("IP") granted to the Company
03-26 21:24
Lexaria Bioscience Launches 2026 R&D Program With Human And Animal GLP-1 Studies To Expand Drug Delivery IP And Business Opportunities
Exciting new human and animal studies designed to enhance business opportunitiesKELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in
03-04 22:28
